Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr 6;33(4):705-706.
doi: 10.1016/j.cmet.2021.03.012.

Obesity therapeutics: The end of the beginning

Fiona M Gribble  1 , Stephen O'Rahilly  2
Affiliations
Free article
Comment

Obesity therapeutics: The end of the beginning

Fiona M Gribble et al. Cell Metab. .
Free article

Abstract

Obese non-diabetic patients receiving semaglutide, an injectable long-acting GLP-1 receptor agonist, in a large randomized placebo-controlled trial, lost and maintained ∼15% of their body weight for over a year (Wilding et al., 2021). This impressive result is likely to usher in a new era of anti-obesity drugs based on hormones that suppress food intake, largely through acting on the brain.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.O.R. has provided remunerated consultancy services to a number of pharmaceutical and biotechnology companies including Pfizer, AstraZeneca Ltd, GSK, Novo-Nordisk, and ERX pharmaceuticals.

Comment on

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.

Substances

LinkOut - more resources